Read this company snapshot
Daily valuation snapshot
Propanc Biopharma, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $0.49
- Market capitalization (USD)
- $3,075,023.04
- Price / earnings (TTM)
- Not reported
- Price / book
- 0.33
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research PPCB in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research PPCB in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing PPCB with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $0.49 |
| Market capitalization (USD) | $3,075,023.04 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.33 |
No matching rows. Clear the filter to see all records.
Read PPCB's valuation metrics
Company size
Propanc Biopharma, Inc. Common Stock's recorded market capitalization is $3,075,023.04. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
PPCB's recorded price-to-book ratio is 0.33. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Propanc Biopharma, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about PPCB. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow PPCB's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.